Proteins and Peptides

02 Nov 2022 Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
01 Nov 2022 Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
01 Nov 2022 FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism
30 Oct 2022 Tavanta Therapeutics to Present Preclinical Data for TAVT-135 at the North American Cystic Fibrosis Conference
24 Oct 2022 Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol® for the Treatment of Dry Eye Disease
17 Oct 2022 Eirion Therapeutics Announces Initiation of First-in-Human Clinical Trial Evaluating Next Generation, Ready-to-Use Liquid Injectable Neuromodulator AI-09 for the Treatment of Wrinkles
17 Oct 2022 Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress
14 Oct 2022 VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Continuity (CIC)
13 Oct 2022 Inotrem Announces Positive Outcome of its Phase II ASTONISH Trial in Septic Shock Patients Demonstrating Efficacy of Nangibotide
08 Oct 2022 First patient treated in Clarity's therapeutic prostate cancer trial
08 Oct 2022 Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206 at the 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
07 Oct 2022 Hugel Aesthetics Resubmits Biologics License Application for LetibotulinumtoxinA for Injection for Glabellar Lines to the FDA
06 Oct 2022 Peptilogics Announces First Patient Dosed in Phase 1b Study of PLG0206 for Periprosthetic Joint Infection
06 Oct 2022 MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
30 Sep 2022 Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)
30 Sep 2022 Trefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery Following Descemet Stripping Only (DSO) Surgery
28 Sep 2022 CinRx Pharma Announces First Study Participant Dosed in CinFina’s Phase I Multiple Ascending Dose (MAD) Study of CIN-109 for the Treatment of Obesity
26 Sep 2022 AEON Biopharma Reports Positive Topline Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia
20 Sep 2022 Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
15 Sep 2022 MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP
15 Sep 2022 Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS)
13 Sep 2022 RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering Actinium-225, into Clinical Development for Two Cancer Indications
13 Sep 2022 Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint
13 Sep 2022 selectION, Inc. Initiates Dosing in Atopic Dermatitis Patients
11 Sep 2022 Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up